The Sr. VP & Ch. Marketing Officer of Express Scripts (NASDAQ: ESRX) is Selling Shares

By Carrie Williams

Today, the Sr. VP & Ch. Marketing Officer of Express Scripts (NASDAQ: ESRX), Anderson Phyllis, sold shares of ESRX for $47.98K.

Following Anderson Phyllis S.’s last ESRX Sell transaction on November 04, 2016, the stock climbed by 6.7%.

Based on Express Scripts’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $25.41 billion and quarterly net profit of $723 million. In comparison, last year the company earned revenue of $25.22 billion and had a net profit of $662 million. The company has a one year high of $89 and a one year low of $64.46. ESRX’s market cap is $45.99B and the company has a P/E ratio of 17.68.

Based on 8 analyst ratings, the analyst consensus is Hold with an average price target of $77.33, reflecting a -3.6% downside. Three different firms, including Deutsche Bank and Jefferies, currently also have a Sell rating on the stock.

The insider sentiment on Express Scripts has been positive according to 68 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Express Scripts Holding Co. engages in the provision of integrated pharmacy benefit management services. Its services include network-pharmacy claims processing, home delivery pharmacy care, specialty pharmacy care, benefit-design consultation, drug utilization review, formulary management, and medical and drug data analysis services. It operates through the Pharmacy Benefit Management (PBM) and Other Business Operations segments. The Pharmacy Benefit Management segment includes clinical solutions to improve health outcomes, specialized pharmacy care, home delivery pharmacy services, specialty pharmacy services, retail network pharmacy administration, benefit design consultation, drug utilization review, and drug formulary management. The Other Business Operations segment provides consulting services for pharmaceutical, biotechnology, and device manufacturers to collect scientific evidence to guide the safe, effective, and affordable use of medicines. The company was founded on July 15, 2011 and is headquartered in St. Louis, MO.